Loading
AVITA Medical, Inc. Stock: price and insider trades · United States
1 insider bought €6,859 of shares over the last 90 days, the latest by O'Toole David D, filed 24 Aug 2026.
AVITA Medical, Inc.: what insiders have been doing
Every trade that managers of AVITA Medical, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 9 insiders have disclosed 26 filings since 22 October 2025.
No insider sold shares on the market over the period. Instead, the filings list 13 purchases totalling €195k, made by 2 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 finance chief and 1 senior executive. Woody Joseph Fralin filed the largest purchase, €19k, on 3 June 2026, which represents 0.0099% of the company's market value.
The data flag 10 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 24 August 2026, 61 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 26 filings, this issuer sits above that mark. Over the whole record (from 2020), the tally stands at 47 purchases and 13 sales. The 10-K for the year ended 31 December 2025 shows 71.6 m USD of revenue and -48.6 m USD of net income.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
135
Thresholds
n/a
Buy Volume
€778,446
47 ops. · all time
Sell Volume
€3M
13 ops. · all time
Who traded when
BuySaleDavid D. O'Toole10 buys
Joseph Fralin Woody9 buys
Robert McNamara4 buys
Suzanne Crowe1 buy
Since the insiders bought
- +6.4%Entry US$1.88 · Close at T+30 US$2.00
- +155.9%Entry US$3.97 · Close at T+90 US$10.16
- +135.4%Entry US$4.29 · Close at T+365 US$10.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate AVITA Medical, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$13.55.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,301 of 26,250 companies
32.7
score / 100
Value18
Quality47
FCF yld-7.0%
Earn yld-10%
EV/EBITDA·
ROE·
Gross mgn82%
Net mgn-68%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.29
Analyst consensus
3 analystsStrong buy
US$11.74Target US$13.55(-11%)US$15.13
Income statement
RevenueUS$71.6M
Gross profitUS$58.8M82% margin
EBITDA-US$41.2M-58% margin
Net income-US$48.6M-57.0% margin
Valuation
PER (forward)-25.4x
Beta1.99
Balance sheet & cash
Market capUS$472.9M
Total debtUS$46M
Free Cash Flow-US$32.9M
Profitability & ownership
ROA-41.6%
% insiders1.5%
% institutions16.3%
Last declaration on 24 August 2026
Declarations135 total
2,000 shares@ US$3.970.0036% mcap2.4% of flowCommon StockSEC:0001193125-26-363747:0
Canonical exit: 10 Sept 2026 (T+90)
2,000 sharesCommon StockSEC:0001193125-26-269544:0
5,200 shares@ US$4.0011.1% of flowCommon StockSEC:0001193125-26-266397:0
Canonical exit: 7 Sept 2026 (T+90)
5,000 shares@ US$4.2011.2% of flowCommon StockSEC:0001193125-26-263968:0
Canonical exit: 7 Sept 2026 (T+90)
5,000 shares@ US$4.1811.1% of flowCommon StockSEC:0001193125-26-263968:1
Canonical exit: 7 Sept 2026 (T+90)
5,000 shares@ US$4.09990.0094% mcap16.3% of flowCommon StockSEC:0001709989-26-000011:0
Canonical exit: 1 Sept 2026 (T+90)
5,000 shares@ US$4.08990.0094% mcap16.2% of flowCommon StockSEC:0001709989-26-000011:1
Canonical exit: 1 Sept 2026 (T+90)
22,214 sharesCommon StockSEC:0001124181-26-000002:0
22,214 sharesCommon StockSEC:0001216486-26-000002:0
22,214 sharesCommon StockSEC:0001387652-26-000001:0
26,250 sharesCommon StockSEC:0001603289-26-000002:0
22,214 sharesCommon StockSEC:0001603289-26-000002:1
40,547 sharesCommon StockSEC:0001709989-26-000008:0
22,214 sharesCommon StockSEC:0001709989-26-000008:1
22,214 sharesCommon StockSEC:0001816242-26-000002:0
5,000 shares@ US$4.18020.0096% mcap16.6% of flowCommon StockSEC:0001709989-26-000006:2
Canonical exit: 31 Aug 2026 (T+90)
5,000 shares@ US$4.260.0098% mcap16.9% of flowCommon StockSEC:0001709989-26-000006:1
Canonical exit: 30 Aug 2026 (T+90)
5,000 shares@ US$4.340.0099% mcap17.2% of flowCommon StockSEC:0001709989-26-000006:0
Canonical exit: 30 Aug 2026 (T+90)
5,000 shares@ US$4.20710.0096% mcap16.7% of flowCommon StockSEC:0001709989-26-000006:3
Canonical exit: 31 Aug 2026 (T+90)
5,000 shares@ US$3.05150.0070% mcap100.0% of flowCommon StockSEC:0001193125-26-251586:0
5,000 shares@ US$3.05150.0070% mcap4.5% of flowCommon StockSEC:0001193125-26-251588:0
2,000 shares@ US$4.240.0039% mcap2.5% of flowCommon StockSEC:0001193125-26-230874:0
Canonical exit: 17 Aug 2026 (T+90)
1,800 shares@ US$4.782.6% of flowCommon StockSEC:0001193125-26-102263:0
Canonical exit: 9 Jun 2026 (T+90)
3,000 shares@ US$4.153.7% of flowCommon StockSEC:0001193125-26-064111:0
Canonical exit: 20 May 2026 (T+90)
105,470 sharesCommon StockSEC:0001193125-26-059552:0
25 of 135 declarations
About AVITA Medical, Inc.
AVITA Medical, Inc. is a U.S.-listed medical technology company traded on the NASDAQ under the symbol AVHHL. For French-speaking investors in Europe, it is best understood as a specialized regenerative medicine business focused on acute wound care, especially burns and traumatic skin injuries. The company’s core platform is RECELL, a cell-based autologous skin treatment system designed to help clinicians treat skin defects using a small sample of the patient’s own skin to create a cell suspension that supports healing. AVITA Medical has also expanded its portfolio with Cohealyx and PermeaDerm, broadening its footprint in advanced wound management.
The company was originally founded in Australia and has since evolved into an international commercial and regulatory platform with operational headquarters in Valencia, California, United States. That U.S. base is strategically important because it places AVITA close to its primary commercial market: leading burn centers, trauma hospitals, and specialized surgical accounts across North America. Its growth story has been built around clinical innovation, regulatory approvals, and incremental expansion of real-world adoption rather than broad consumer-facing commercialization.
Read moreShow less
From a competitive standpoint, AVITA Medical occupies a niche but potentially high-value segment of wound care. It competes against conventional split-thickness skin grafting and other advanced wound-care solutions. Its value proposition is centered on conserving donor skin, potentially accelerating wound closure, and improving the treatment pathway for complex burns and traumatic wounds. That differentiation is important in specialized hospital settings where clinical outcomes, operating-room efficiency, and resource utilization matter materially.
Recent company updates have emphasized commercial execution, portfolio expansion, and international progress. A key development was the CE Mark approval for RECELL GO in Europe, which supports a broader international rollout and reinforces AVITA’s ambition to become a more global acute wound-care platform. Management has also highlighted operational discipline, including cost reductions and improving cash efficiency, while guiding toward a recovery in revenue momentum into 2026. For full-year 2025, AVITA Medical reported revenue of about $71.6 million and signaled an expectation of gradual normalization in clinician use of RECELL.
Overall, AVITA Medical remains a differentiated but still execution-dependent medtech name on the NASDAQ in the United States. Its investment case hinges on deeper penetration within burn and trauma centers, continued regulatory and clinical validation, and the company’s ability to translate product innovation into sustainable commercial growth.
